Outcome of inotropic therapy: Is less always more?

Current Opinion in Anaesthesiology

Volumn 28, Issue 2, 2015, Pages 159-164

  Nielsen, Dorthe Viemose ^a   Algotsson, Lars ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

heart failure; inotropic agents; morbidity; mortality; outcome

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ADRENALIN; CARDIAC MYOSIN; DOBUTAMINE; DOPAMINE; DOPEXAMINE; ENOXIMONE; HYPERTENSIVE FACTOR; INOTROPIC AGENT; ISTAROXIME; LEVOSIMENDAN; MILRINONE; NORADRENALIN; OMECAMTIV MECARBIL; PARVOVIRUS VECTOR; PHOSPHODIESTERASE III INHIBITOR; CARDIOTONIC AGENT; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE;

CARDIOGENIC SHOCK; CARDIOPULMONARY BYPASS; CARDIOVASCULAR MORTALITY; FORWARD HEART FAILURE; GENE THERAPY; HEART ARRHYTHMIA; HEART FAILURE; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HEART RATE; HEART SURGERY; HUMAN; HYPOTENSION; ISCHEMIC HEART DISEASE; MORBIDITY; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; REVIEW; RISK ASSESSMENT; SARCOPLASMIC RETICULUM; SEPTIC SHOCK; STANDARDIZATION; SYSTEMIC VASCULAR RESISTANCE; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TRANSGENE; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIAC OUTPUT, LOW; CRITICAL ILLNESS; INTENSIVE CARE; PATHOPHYSIOLOGY; PROCEDURES; SHOCK, SEPTIC;

ANIMALS; CARDIAC OUTPUT, LOW; CARDIOTONIC AGENTS; CRITICAL CARE; CRITICAL ILLNESS; HUMANS; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SHOCK, SEPTIC;

EID: 84926407906     PISSN: 09527907     EISSN: 14736500     Source Type: Journal    
DOI: 10.1097/ACO.0000000000000157     Document Type: Review

References (29)

1. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 128: e240-e327.
2. McMurray JJ, Adamopoulos S, AnkerSD, et al. ESCguidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787-1847.
3. Francis GS, Bartos JA, Adatya S. Inotropes. J Am Coll Cardiol 2014; 63: 2069-2078.
4. Allen LA, Fonarow GC, Grau-Sepulveda MV, et al. Hospital variation in intravenous inotrope use for patients hospitalized with heart failure: insights from Get With The Guidelines. Circ Heart Fail 2014; 7: 251-260.
5. Nielsen DV, Johnsen SP, Madsen M, Jakobsen CJ. Variation in use of peroperative inotropic support therapy in cardiac surgery: time for reflection? Acta Anaesthesiol Scand 2011; 55: 352-358.
6. Nielsen DV, Hansen MK, Johnsen SP, et al. Health outcomes with and without use of inotropic therapy in cardiac surgery: results of a propensity scorematched analysis. Anesthesiology 2014; 120: 1098-1108.
7. Fleming GA, Murray KT, Yu C, et al. Milrinone use is associated with postoperative atrial fibrillation after cardiac surgery. Circulation 2008; 118: 1619-1625.
8. Harrison RW, Hasselblad V, Mehta RH, et al. Effect of levosimendan on survival and adverse events after cardiac surgery: a meta-analysis. J Cardiothorac Vasc Anesth 2013; 27: 1224-1232.
9. Majure DT, Greco T, Greco M, et al. Meta-analysis of randomized trials of effect of milrinone on mortality in cardiac surgery: an update. J Cardiothorac Vasc Anesth 2013; 27: 220-229.
10. Cuffe MS, Califf RM, Adams KF Jr, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002; 287: 1541-1547.
11. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007; 297: 1883-1891.
12. Amsallem E, Kasparian C, Haddour G, et al. Phosphodiesterase III inhibitors for heart failure. Cochrane Database Syst Rev 2005; (1): CD002230.
13. Kalogeropoulos AP, Marti CN, Georgiopoulou VV, Butler J. Inotrope use and outcomes among patients hospitalized for heart failure: impact of systolic blood pressure, cardiac index, and etiology. J Card Fail 2014; 20: 593-601.
14. Felker GM, Benza RL, Chandler AB, et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 2003; 41: 997-1003.
15. Pirracchio R, Parenica J, Resche Rigon M, et al. The effectiveness of inodilators in reducing short term mortality among patient with severe cardiogenic shock: a propensity-based analysis. PLoS One 2013; 8: e71659.
16. Delaney A, Bradford C, McCaffrey J, et al. Levosimendan for the treatment of acute severe heart failure: a meta-analysis of randomised controlled trials. Int J Cardiol 2010; 138: 281-289.
17. Unverzagt S, Wachsmuth L, Hirsch K, et al. Inotropic agents and vasodilator strategies for acute myocardial infarction complicated by cardiogenic shock or low cardiac output syndrome. Cochrane Database Syst Rev 2014; 1: CD009669.
18. ProCESS Investigators. Yealy DM, Kellum JA, Huang DT, et al. A randomized trial of protocol-based care for early septic shock. N Engl J Med 2014; 370: 1683-1693.
19. ARISE Investigators; ANZICS Clinical Trials Group. Peake SL, Delaney A, BaileyM, et al. Goal-directed resuscitation for patients with early septic shock. N Engl J Med 2014; 371: 1496-1506.
20. Annane D, Vignon P, Renault A, et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet 2007; 370: 676-684.
21. Mark DG, Morehouse JW, Hung YY, et al. In-hospital mortality following treatment with red blood cell transfusion or inotropic therapy during early goaldirected therapy for septic shock: a retrospective propensity-adjusted analysis. Crit Care 2014; 18: 496.
22. Oba Y, Lone NA. Mortality benefit of vasopressor and inotropic agents in septic shock: a Bayesian network meta-analysis of randomized controlled trials. J Crit Care 2014; 29: 706-710.
23. Pearse RM, Harrison DA, MacDonald N, et al. Effect of a perioperative, cardiac output-guided hemodynamic therapy algorithm on outcomes following major gastrointestinal surgery: a randomized clinical trial and systematic review. JAMA 2014; 311: 2181-2190.
24. Arulkumaran N, Corredor C, Hamilton MA, et al. Cardiac complications associated with goal-directed therapy in high-risk surgical patients: a metaanalysis. Br J Anaesth 2014; 112: 648-659.
25. Malik FI, Hartman JJ, Elias KA, et al. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science 2011; 331: 1439-1443.
26. Cleland JG, Teerlink JR, Senior R, et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet 2011; 378: 676-683.
27. Gheorghiade M, Blair JE, Filippatos GS, et al. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. J Am Coll Cardiol 2008; 51: 2276-2285.
28. Jessup M, Greenberg B, Mancini D, et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+- ATPase in patients with advanced heart failure. Circulation 2011; 124: 304-313.
29. Zsebo K, Yaroshinsky A, Rudy JJ, et al. Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. Circ Res 2014; 114: 101-108.